Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of FT-003 in Subjects With Neovascular Age-related Macular Degeneration

NCT05611424 is registered in ClinicalTrials.gov with Frontera Therapeutics as lead sponsor.

NCT NCT05611424
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05611424 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of FT-003 in Subjects With Neovascular Age-related Macular Degeneration
Lead sponsor
Frontera Therapeutics
Phase
Phase 1
Overall status
Not yet recruiting
Start date
May 1, 2023
Completion date
December 30, 2027
Enrollment
18 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration